Menu
← Oncology Approval Tracker
FDA DECISION ·
Gavreto
pralsetinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy that was refractory to radioactive iodine when radioactive iodine was appropriate.
LAMPGEN ANALYSIS
Why it matters
Expanded pralsetinib to a RET fusion-positive thyroid cancer population under accelerated approval.
What research teams should watch
Confirm fusion status and document prior or unsuitable radioactive iodine before applying the historical label.
PRIMARY RECORDS